These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 37565288)

  • 1. Results of the SEL-I-METRY Phase II Trial on Resensitization of Advanced Iodine Refractory Differentiated Thyroid Cancer to Radioiodine Therapy.
    Wadsley J; Ainsworth G; Coulson AB; Garcez K; Moss L; Newbold K; Farnell K; Swain J; Howard H; Beasley M; Weaver A; Wood K; Marshall J; Griffin M; Pascoe A; Du Y; Taprogge J; Flux G; Brown S
    Thyroid; 2023 Sep; 33(9):1119-1123. PubMed ID: 37565288
    [No Abstract]   [Full Text] [Related]  

  • 2. Investigating the potential clinical benefit of Selumetinib in resensitising advanced iodine refractory differentiated thyroid cancer to radioiodine therapy (SEL-I-METRY): protocol for a multicentre UK single arm phase II trial.
    Brown SR; Hall A; Buckley HL; Flanagan L; Gonzalez de Castro D; Farnell K; Moss L; Gregory R; Newbold K; Du Y; Flux G; Wadsley J
    BMC Cancer; 2019 Jun; 19(1):582. PubMed ID: 31200667
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advances in the molecular mechanism and targeted therapy of radioactive-iodine refractory differentiated thyroid cancer.
    Zhang L; Li Z; Zhang M; Zou H; Bai Y; Liu Y; Lv J; Lv L; Liu P; Deng Z; Liu C
    Med Oncol; 2023 Jul; 40(9):258. PubMed ID: 37524925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radioiodine Refractory Differentiated Thyroid Cancer.
    Chan WWL; Chan S; Kwong DLW
    Methods Mol Biol; 2022; 2534():243-257. PubMed ID: 35670980
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Thyroid; 2023 Nov; 33(11):1385. PubMed ID: 37856079
    [No Abstract]   [Full Text] [Related]  

  • 6. Target therapies for radioiodine refractory advanced thyroid tumors.
    Schlumberger M
    J Endocrinol Invest; 2012; 35(6 Suppl):40-4. PubMed ID: 23014073
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted therapy in radioiodine refractory thyroid cancer.
    Pacini F; Brilli L; Marchisotta S
    Q J Nucl Med Mol Imaging; 2009 Oct; 53(5):520-5. PubMed ID: 19910905
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Redifferentiating agents in non-radioiodine avid cancer.
    Seregni E; Vellani C; Castellani MR; Maccauro M; Pallotti F; Scaramellini G; Guzzo M; Greco A
    Q J Nucl Med Mol Imaging; 2009 Oct; 53(5):513-9. PubMed ID: 19910904
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of multikinase inhibitors/lenvatinib concomitant with radioiodine for the treatment of radioiodine refractory differentiated thyroid cancer.
    Herranz UA
    Cancer Med; 2022 Oct; 11 Suppl 1(Suppl 1):47-53. PubMed ID: 36202606
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Feasibility of Apatinib in Radioiodine-Refractory Differentiated Thyroid Carcinoma.
    Du W; Shi X; Fang Q; Zhang X; Liu S
    Front Endocrinol (Lausanne); 2022; 13():768028. PubMed ID: 35282451
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Drug approval: Cabozantinib monotherapy in advanced thyroid cancers refractory or not eligible for radioactive iodine treatment, after progression under previous systemic therapies].
    Matte P; Hadoux J
    Bull Cancer; 2022 Nov; 109(11):1103-1104. PubMed ID: 36220695
    [No Abstract]   [Full Text] [Related]  

  • 12. Update on iodine-refractory differentiated thyroid carcinoma.
    Abou Jokh Casas E; Repetto A; Rodriguez Gasén A; Vercher Conejero JL; Bello Arques P; Cambil Molina T; Vallejo Casas JA
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2023; 42(5):325-334. PubMed ID: 37442524
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted treatments of radio-iodine refractory differentiated thyroid cancer.
    de la Fouchardière C
    Ann Endocrinol (Paris); 2015 Feb; 76(1 Suppl 1):1S34-9. PubMed ID: 26826481
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lenvatinib - A multikinase inhibitor for radioiodine-refractory differentiated thyroid cancer.
    Hewett Y; Ghimire S; Farooqi B; Shah BK
    J Oncol Pharm Pract; 2018 Jan; 24(1):28-32. PubMed ID: 27856921
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The medical treatment of radioiodine-refractory differentiated thyroid cancers in 2019. A TUTHYREF
    de la Fouchardiere C; Alghuzlan A; Bardet S; Borget I; Borson Chazot F; Do Cao C; Godbert Y; Leenhardt L; Zerdoud S; Leboulleux S
    Bull Cancer; 2019 Sep; 106(9):812-819. PubMed ID: 31200896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advanced radioiodine-refractory differentiated thyroid cancer: the sodium iodide symporter and other emerging therapeutic targets.
    Spitzweg C; Bible KC; Hofbauer LC; Morris JC
    Lancet Diabetes Endocrinol; 2014 Oct; 2(10):830-42. PubMed ID: 24898835
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radioiodine for High Risk and Radioiodine Refractory Thyroid Cancer: Current Concepts in Management.
    Newbold KL; Flux G; Wadsley J
    Clin Oncol (R Coll Radiol); 2017 May; 29(5):307-309. PubMed ID: 28139379
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimizing therapy for radioactive iodine-refractory differentiated thyroid cancer: current state of the art and future directions.
    Dadu R; Cabanillas ME
    Minerva Endocrinol; 2012 Dec; 37(4):335-56. PubMed ID: 23235190
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term analysis of the efficacy and tolerability of sorafenib in advanced radio-iodine refractory differentiated thyroid carcinoma: final results of a phase II trial.
    Schneider TC; Abdulrahman RM; Corssmit EP; Morreau H; Smit JW; Kapiteijn E
    Eur J Endocrinol; 2012 Nov; 167(5):643-50. PubMed ID: 22918300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging strategies for managing differentiated thyroid cancers refractory to radioiodine.
    Bulotta S; Celano M; Costante G; Russo D
    Endocrine; 2016 May; 52(2):214-21. PubMed ID: 26690657
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.